324 related articles for article (PubMed ID: 19194126)
1. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Yamaguchi T; Matsumoto H; Yasutome M; Mori T; Takahashi K
Cancer Chemother Pharmacol; 2011 Mar; 67(3):629-35. PubMed ID: 20495917
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
10. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
[TBL] [Abstract][Full Text] [Related]
13. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
16. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
[TBL] [Abstract][Full Text] [Related]
17. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Price T; Hill M
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Idelevich E; Greif F; Mavor E; Miller R; Kashtan H; Susmalian S; Ariche A; Brenner B; Baruch NB; Dinerman M; Shani A
Chemotherapy; 2009; 55(2):76-82. PubMed ID: 19077422
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
